CSPC Pharmaceutical Group Limited (1093.HK)

Executive Summary

CSPC Pharmaceutical Group Limited (1093.HK) is a leading China-based pharmaceutical company with a diversified portfolio spanning branded generics, innovative drugs, and APIs. The company focuses on therapeutic areas such as oncology, cardiovascular, and central nervous system diseases. With over 40 years of operational history, CSPC has built a strong commercial presence in China and is increasingly investing in R&D to transition toward innovative drugs. Its pipeline includes multiple clinical-stage candidates, particularly in oncology and cardiovascular indications, which are expected to drive future growth. The company's integrated manufacturing capabilities, certified to international standards, support both domestic and export sales. Despite near-term headwinds from China's volume-based procurement (VBP) policies, CSPC's robust pipeline and established generics business provide a foundation for sustained performance. CSPC's key near-term value drivers include the Phase 3 readout of butylphthalide for ST-segment elevation myocardial infarction (STEMI), which could expand its cardiovascular franchise. Additionally, the Phase 2 trial of a Venetoclax-based combination regimen for acute myeloid leukemia (AML) is advancing, with completion expected by end-2026. The company also has early-stage assets in immuno-oncology and liposomal formulations. While competition in China remains intense, CSPC's scale, R&D investment, and regulatory expertise position it to capture market share in high-growth areas. The conviction score reflects a balanced risk/reward profile, with upside from pipeline milestones and downside from regulatory and pricing risks.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Data Readout for Butylphthalide in STEMI75% success
• Q4 2026Phase 2 AML Trial Completion (Venetoclax Combination Regimen)50% success
• TBDPotential NDA Submission for Novel Drug Candidates40% success